Terms: = Lymphoma AND MYB, c-myb_CDS, 4602, ENSG00000118513, P10242, efg, Cmyb, c-myb AND Clinical Outcome
2 results:
1. Harnessing the myb-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
[TBL] [Abstract] [Full Text] [Related]
2. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract] [Full Text] [Related]
